A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)

NG-641 - PsiOxus

Opdivo (nivolumab) - Ono Pharma, BMS

enadenotucirev (ColoAd1) - PsiOxus, BMS

Tom Lillie, Eileen Parkes, Christian Ottensmeier, David Krige, Behnaz Ravanfar, Vladimir Evilevitch, Matthew Thomas, Lee Rosen

Mar 9, 2022